arrow
A

AjazMazhar (Anthony J. Chalmers)

university of glasgow
H指数:48
被引数:9,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ESTRO, ESNR, and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumors

ESTRO、ESNR和EORTC基于共识的颅内中枢神经系统肿瘤放疗后MRI异常定义

2026-08-200
PRE
Development of a novel analytical pipeline to characterize morphological and molecular features of blood vessels within marginal regions of glioblastoma

开发一种新型分析流程以表征胶质母细胞瘤边缘区域血管的形态学和分子学特征

2026-07-300
OA
Clinical application of 1H MRS in the human brain at 7T

7T人体脑1H MRS的临床应用

2026-04-300
OAAI
Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma

类固醇依赖性代谢重组揭示了胶质母细胞瘤的新治疗和成像方法

2026-01-230
OAAI
A global, open-label, randomized Phase 3 trial evaluating niraparib compared to standard temozolomide therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

一项全球、开放标签、随机III期临床试验,评估尼拉帕利与标准替莫唑胺疗法在 newly diagnosed、MGMT-unmethylated glioblastoma 患者中的比较。

2025-11-010
OAAI
MOLECULAR AND MORPHOLOGICAL FEATURES OF BLOOD VESSELS IN TUMOUR MARGIN REGIONS OF GLIOBLASTOMA ARE DISTINCT FROM TUMOUR CORE AND NORMAL BRAIN, AND DRUG DELIVERY IS REDUCED

胶质母细胞瘤边缘区域的血管分子和形态学特征与肿瘤核心及正常脑组织不同,且药物递送减少。

2025-10-010
OAAI
A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.

一项全球性III期、开放标签、随机对照研究,针对新诊断的MGMT未甲基化胶质母细胞瘤,比较Niraparib与标准护理替莫唑胺治疗。

2025-10-010
OAAI
RESULTS OF THE MGMT METHYLATED SUBSTUDY OF PARADIGM: A PHASE I STUDY OF OLAPARIB WITH RADIOTHERAPY AND TEMOZOLOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

PARADIGM研究中MGMT甲基化亚组的研究结果:一项在 newly diagnosed glioblastoma 老年患者中联合奥拉帕利、放疗和替莫唑胺的I期研究

2025-10-010
OAAI
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of Glioblastoma

发现一种强效、选择性且能透过血脑屏障的检查点激酶1抑制剂BEN-28010,用于胶质母细胞瘤的治疗

2025-04-240
PRE